BMO Capital analyst John McNulty maintained a Buy rating on TRONOX (TROX – Research Report) today and set a price target of $28.00. The company’s shares closed last Tuesday at $16.64, close to its 52-week low of $15.44.
According to TipRanks.com, McNulty is a 3-star analyst with an average return of 1.2% and a 45.0% success rate. McNulty covers the Basic Materials sector, focusing on stocks such as Air Products and Chemicals, Sherwin-Williams Company, and Axalta Coating Systems.
Currently, the analyst consensus on TRONOX is a Strong Buy with an average price target of $26.00, representing a 62.5% upside. In a report issued on June 6, Alembic Global also maintained a Buy rating on the stock with a $31.00 price target.
The company has a one-year high of $26.33 and a one-year low of $15.44. Currently, TRONOX has an average volume of 902.3K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TROX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tronox Holdings Plc engages in the mining and inorganic chemical business. Its products include Titanium Dioxide Mineral Sands. The firm also mines and processes titanium ore, zircon and other minerals, and manufactures titanium dioxide pigments. The company was founded in March 2012 and is headquartered in Stamford, CT.
Read More on TROX:
- BMO Capital Reiterates a Buy Rating on Chemours Company (CC)
- EOG Resources (EOG) Receives a Buy from BMO Capital
- Analysts Conflicted on These Technology Names: Gartner (IT) and Avalara (AVLR)
- Monness Sticks to Its Hold Rating for Splunk (SPLK)
- Analysts Offer Insights on Healthcare Companies: SQZ Biotechnologies (SQZ) and AVEO Pharma (AVEO)